
    
      This is a single-arm phase 2 study in adults with Sickle Cell Disease (SCD) to assess the
      effect of oral isoquercetin on biomarkers of endothelial and platelet activation,
      inflammation and ongoing blood coagulation.

        -  The research study procedures include screening for eligibility and study treatment
           including evaluations and follow up visits.

             -  The names of the study drug involved in this study are/is: Isoquercetin

             -  Participants will receive study treatment for 1 year and will be followed for 30
                days after the last dose.

        -  This research study is a Phase II clinical trial. Phase II clinical trials test the
           safety and effectiveness of an investigational drug to learn whether the drug works in
           treating a specific disease. "Investigational" means that the drug is being studied.

        -  The U.S. Food and Drug Administration (FDA) has not approved isoquercetin as a treatment
           for any disease.
    
  